PROSTATE CANCER

MAOA inhibitor phenelzine efficacious in recurrent prostate cancer

The results of a phase II clinical trial investigating the monoamine oxidase (MAOA) inhibitor phenelzine in biochemically recurrent, hormone-sensitive prostate cancer have been published. In this open-label, single-arm clinical trial, 20 patients were recruited to receive 30 mg of phenelzine orally twice daily. The primary end point was the proportion of patients achieving a serum PSA decline of ≥50% from baseline and mood symptoms were assessed using the hospital anxiety depression score questionnaire. The results showed that 10% of patients had a maximal PSA level decline of ≥50% and 25% of patients showed declines of ≥30%. At 12 weeks after commencing treatment, 17 patients were still receiving phenelzine. Of these men, 20% had PSA declines of ≥30% and 5% had declines of ≥50%. Questionnaire results showed that anxiety decreased but depressive symptoms did not change. Rare, considerable but reversible cardiovascular toxic effects were observed; however, most treatment-related toxic effects were mild. Thus, MAOA inhibitors are a promising treatment option for men with recurrent, hormone-sensitive prostate cancer.

References

Original article

  1. Gross, M. E. et al. Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-020-0211-9 (2020)

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Louise Stone.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stone, L. MAOA inhibitor phenelzine efficacious in recurrent prostate cancer. Nat Rev Urol 17, 192 (2020). https://doi.org/10.1038/s41585-020-0307-y

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing